- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02047149
Evaluating the Safety of Zileuton (Zyflo®) in Combination With Dasatinib (Sprycel®) in Chronic Myelogenous Leukemia
Phase I Study to Evaluate the Safety of Zileuton (Zyflo®) in Combination With Dasatinib (Sprycel®) in Patients With Chronic Myelogenous Leukemia
Prospective nonrandomized phase I study
The purpose of this study is to determine safety and efficacy of zileuton when added to dasatinib in patients with chronic myelogenous leukemia (CML).
Study Overview
Status
Conditions
Detailed Description
The standard treatment for chronic myelogenous leukemia is therapy with tyrosine kinase inhibitors (TKIs). This treatment can diminish the amount of disease to very low levels that only very sensitive and specialized techniques can measure; it does not, however, provide a cure.
Dr. Shaoguang Li and colleagues at University of Massachusetts have published a unique discovery that the arachidonate 5-lipoxygenase (5-LO) gene (Alox5) is a critical regulator for LSCs in BCR-ABL-induced CML (Chen Y et al. Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia. Nature Genetics 41:783-792, 2009). In the absence of Alox5, BCR-ABL failed to induce CML in preclinical studies. While deficiency in Alox5 had no effect on normal hematopoiesis, impairment of the LSCs function through differentiation and cell division of CML LSCs was observed. This defect led to a depletion of LSCs and a failure of CML development. Treatment with a 5-LO inhibitor (zileuton) also impaired the function of LSCs and prolonged survival. These results demonstrate that a specific target gene can be found in cancer stem cells and its inhibition can completely inhibit the function of these stem cells. These findings provide an exciting opportunity to develop the first anti-cancer stem cell therapy for treating CML.
Patients who did not respond or did not tolerate two TKIs will be considered for this study.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Worcester, Massachusetts, United States, 01655
- University of Massachusetts Medical School
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Target Population:
1. Patients with CML with known inadequate response (as appropriate for their CML status) to TKIs or known resistance will be considered for this study
- Patients who are resistant or not responding adequately to dasatinib as a first line therapy, but are not able or eligible to receive other effective second line treatment can be considered for participation in the study.
- Age > 18 years
- ECOG performance status ≤ 2
- Total bilirubin < 2.0 times the institutional Upper Limit of Normal (ULN)
- Hepatic enzymes (AST, ALT ) ≤ 1.5 times the institutional ULN
- Serum Na, K+, Mg2+, Phosphate and Ca2+>= Lower Limit of Normal (LLN)
- Serum Creatinine < 2.3 mg/dL
- PT, PTT all Grade 0-1 3) Ability to take oral medication 4) Concomitant Medications
- Patient agrees to discontinue St. Johns Wort while receiving dasatinib therapy 5) Age and Sex
- Women of childbearing potential and men of fathering potential must use an adequate method of contraception to avoid pregnancy throughout the study to minimize the risk of pregnancy
Exclusion Criteria:
Sex and Reproductive Status
- Women of childbearing potential and men of fathering potential unable or unwilling to use an adequate method of contraception to avoid pregnancy throughout the study to minimize the risk of pregnancy
Target Population
- Patients intolerant of dasatinib.
Medical History and Concurrent Diseases
- History of active malignancy during the past 5 years with the exception of nonmetastatic treated skin cancer (e.g. basal or squamous cell carcinoma ) or stage 0 cervical carcinoma
- Patients known to be HIV-positive
- Patients with active, uncontrolled infections
- Concurrent medical condition which may increase the risk of toxicity, including:
- Pleural or pericardial effusion of any grade
- Cardiac Conditions:
- Uncontrolled angina, congestive heart failure or MI within (6 months)
- Diagnosed congenital long QT syndrome
- Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades de pointes)
- Prolonged QTc interval on pre-entry electrocardiogram (> 450 msec)
- Severe cardiac dysfunction (NYHA classification III-IV)
- Severe pulmonary disease
- History of significant bleeding disorder unrelated to cancer
Physical and Laboratory Test Findings
- Hepatic dysfunction (serum bilirubin ≥ 2 x ULN, and/or ALT ≥ 3 x ULN, and/or AST ≥ 3 x ULN)
- Renal dysfunction (creatinine ≥ 200 μmol/l or 2.3 mg/dl)
- Subjects with hypokalemia or hypomagnesemia that cannot be corrected prior to dasatinib administration
Allergies and Adverse Drug Reactions
- Patients with known allergic reaction or intolerance to either dasatinib or zileuton
Prohibited Treatments and/or Therapies
- Category I drugs that are generally accepted to have a risk of causing Torsades de Pointes including:
- quinidine, procainamide, disopyramide
- amiodarone, sotalol, ibutilide, dofetilide
- erythromycin, clarithromycin
- chlorpromazine, haloperidol, mesoridazine, thioridazine, pimozide
- cisapride, bepridil, droperidol, methadone, arsenic, chloroquine, domperidone, halofantrine, levomethadyl, pentamidine, sparfloxacin, lidoflazine.
- Patients requiring anticoagulation with Coumadin
Other Exclusion Criteria
- Prisoners or subjects who are involuntarily incarcerated.
- Subjects who are compulsorily detained for treatment of either a psychiatric or physical (e.g. infectious disease) illness.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Zileuton/Dasatinib
zileuton/dasatinib: This is a traditional phase I design.
Three dose levels of daily zileuton will be studied in conjunction with dasatinib to define the MTD
|
To determine the maximum dose of zileuton/dasatinib in subjects with CML
Three dose levels of daily zileuton will be studied in conjunction with dasatinib to define the MTD
Other Names:
Three dose levels of daily zileuton will be studied in conjunction with dasatinib to define the MTD
Other Names:
Three dose levels of daily zileuton will be studied in conjunction with dasatinib to define the MTD
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine the maximal tolerated dose (MTD) of zileuton when added to dasatinib in patients with CML
Time Frame: 36 mos
|
36 mos
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To assess the efficacy of zileuton combined with dasatinib in terms of:
Time Frame: 36 mos
|
|
36 mos
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Jan Cerny, MD, PhD, University of Massachusetts, Worcester
Publications and helpful links
General Publications
- Chen Y, Hu Y, Zhang H, Peng C, Li S. Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia. Nat Genet. 2009 Jul;41(7):783-92. doi: 10.1038/ng.389. Epub 2009 Jun 7.
- Shah NP, Kantarjian HM, Kim DW, Rea D, Dorlhiac-Llacer PE, Milone JH, Vela-Ojeda J, Silver RT, Khoury HJ, Charbonnier A, Khoroshko N, Paquette RL, Deininger M, Collins RH, Otero I, Hughes T, Bleickardt E, Strauss L, Francis S, Hochhaus A. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol. 2008 Jul 1;26(19):3204-12. doi: 10.1200/JCO.2007.14.9260. Epub 2008 Jun 9.
- Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science. 1990 Feb 16;247(4944):824-30. doi: 10.1126/science.2406902.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Bone Marrow Diseases
- Hematologic Diseases
- Myeloproliferative Disorders
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Protein Kinase Inhibitors
- Leukotriene Antagonists
- Hormone Antagonists
- Antisickling Agents
- Lipoxygenase Inhibitors
- Hydroxyurea
- Dasatinib
- Zileuton
Other Study ID Numbers
- CA 180-338
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Myelogenous Leukemia
-
National Cancer Institute (NCI)CompletedChildhood Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 PositiveUnited States
-
National Cancer Institute (NCI)TerminatedAccelerated Phase Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 PositiveUnited States
-
National Cancer Institute (NCI)CompletedChronic Phase Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 PositiveUnited States
-
National Cancer Institute (NCI)CompletedChildhood Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 PositiveUnited States
-
National Cancer Institute (NCI)TerminatedAccelerated Phase Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Blastic Phase Chronic Myelogenous LeukemiaUnited States
-
National Cancer Institute (NCI)CompletedChronic Phase Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 PositiveUnited States
-
National Cancer Institute (NCI)CompletedAccelerated Phase Chronic Myelogenous Leukemia | Childhood Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Blastic Phase Chronic Myelogenous LeukemiaUnited States
-
Medical College of WisconsinH. Jean Khoury Cure CML ConsortiumRecruiting
-
M.D. Anderson Cancer CenterNovartisCompletedLeukemia, Myelogenous, ChronicUnited States
-
The University of Hong KongUnknownCessation of Tyrosine Kinase Inhibitors in Patients With Chronic-phase Chronic Myelogenous LeukaemiaLeukemia, Myelogenous, Chronic PhaseHong Kong
Clinical Trials on Zileuton (Zyflo®) Dasatinib (Sprycel®)
-
Grupo Espanol de trasplantes hematopoyeticos y...CompletedLeukemia, Lymphoblastic, Acute, Philadelphia-PositiveSpain
-
University of JenaCompleted
-
Merck Sharp & Dohme LLCTerminatedChronic Myelogenous Leukemia | Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
-
H. Lee Moffitt Cancer Center and Research InstituteBristol-Myers SquibbTerminated
-
H. Lee Moffitt Cancer Center and Research InstituteBristol-Myers SquibbCompletedMyelodysplastic SyndromesUnited States
-
St. Jude Children's Research HospitalCompletedDiffuse Intrinsic Pontine Glioma | High-grade GliomaUnited States
-
Bristol-Myers SquibbTerminatedLeukemiaFrance, United States, Spain, Poland, Finland, Argentina, Canada, Belgium
-
University of California, IrvineBristol-Myers SquibbCompletedRecurrent Prostate Cancer | Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Hormone-refractory Prostate CancerUnited States
-
Bristol-Myers SquibbTerminated
-
H. Lee Moffitt Cancer Center and Research InstituteBristol-Myers SquibbCompletedNon-Small-Cell Lung CarcinomaUnited States